| 词条 | Benzatropine |
| 释义 |
{{drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 456483119 | IUPAC_name = (3-endo)-3-(Diphenylmethoxy)-8-methyl-8-azabicyclo[3.2.1]octane | image = Benzatropine.svg | image2 = Benzatropina.gif | tradename = Cogentin, others | Drugs.com = {{drugs.com|monograph|cogentin}} | pregnancy_US = C | pregnancy_category = | legal_US = Rx-only | routes_of_administration = By mouth, IM, IV | bioavailability = | metabolism = Hepatic | elimination_half-life = 12-24 hours | excretion = Urine | IUPHAR_ligand = 7601 | synonyms = Benztropine | CAS_number_Ref = {{cascite|correct|??}} | CAS_number = 86-13-5 | ATC_prefix = N04 | ATC_suffix = AC01 | PubChem = 1201549 | DrugBank_Ref = {{drugbankcite|changed|drugbank}} | DrugBank = DB00245 | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID = 16736541 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = 1NHL2J4X8K | ChEBI_Ref = {{ebicite|correct|EBI}} | ChEBI = 3048 | ChEMBL_Ref = {{ebicite|changed|EBI}} | ChEMBL = 1201203 | C=21 | H=25 | N=1 | O=1 | molecular_weight = 307.429 g/mol | smiles = CN4[C@@H]1CC[C@H]4C[C@H](C1)OC(c2ccccc2)c3ccccc3 | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI = 1S/C21H25NO/c1-22-18-12-13-19(22)15-20(14-18)23-21(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18-21H,12-15H2,1H3/t18-,19+,20+ | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | StdInChIKey = GIJXKZJWITVLHI-PMOLBWCYSA-N | USAN=benztropine | BAN=benztropine }} Benzatropine, also known as benztropine, is an anticholinergic marketed under the trade name Cogentin which is used in the treatment of Parkinson's disease, Parkinsonism, and dystonia. In 2016 it was the 211th most prescribed medication in the United States with more than 2 million prescriptions.[1] Medical usesBenzatropine is an anticholinergic drug used in patients to reduce extrapyramidal side effects of antipsychotic treatment. Benzatropine is also a second-line drug for the treatment of Parkinson's disease. It improves tremor, and may alleviate rigidity and bradykinesia.[2] Benzatropine is also sometimes used for the treatment of dystonia, a rare disorder that causes abnormal muscle contraction, resulting in twisting postures of limbs, trunk, or face. In veterinary medicine, benzatropine is used to treat priapism in stallions.[3] Adverse effectsThese are principally anticholinergic:
While some studies suggest that use of anticholinergics increases the risk of tardive dyskinesia (a long-term side effect of antipsychotics),[4][5] other studies have found no association between anticholinergic exposure and risk of developing tardive dyskinesia,[6] although symptoms may be worsened.[7] Drugs that decrease cholinergic transmission may impair storage of new information into long-term memory. Anticholinergic agents can also impair time perception.[8] PharmacologyBenzatropine is a centrally acting anticholinergic/antihistamine agent. It is a selective M1 muscarinic acetylcholine receptor antagonist. Benzatropine partially blocks cholinergic activity in the basal ganglia and has also been shown to increase the availability of dopamine by blocking its reuptake and storage in central sites, and as a result, increasing dopaminergic activity. Animal studies have indicated that anticholinergic activity of benzatropine is approximately one-half that of atropine, while its antihistamine activity approaches that of mepyramine. Its anticholinergic effects have been established as therapeutically significant in the management of Parkinsonism. Benzatropine antagonizes the effect of acetylcholine, decreasing the imbalance between the neurotransmitters acetylcholine and dopamine, which may improve the symptoms of early Parkinson's disease.[9] Benzatropine analogues are atypical dopamine reuptake inhibitors,[10] which might make them useful for people with akathisia secondary to antipsychotic therapy.[11] Benzatropine also acts as a functional inhibitor of acid sphingomyelinase (FIASMA).[12] Benzatropine has been also identified, by a high throughput screening approach, as a potent differentiating agent for oligodendrocytes, possibly working through M1 and M3 muscarinic receptors. In preclinical models for multiple sclerosis, benzatropine decreased clinical symptoms and enhanced re-myelination.[13] See also
References1. ^{{cite web |title=The Top 300 of 2019 |url=https://clincalc.com/DrugStats/Top300Drugs.aspx |website=clincalc.com |accessdate=22 December 2018}} {{Antiparkinson}}{{Histamine receptor modulators}}{{Monoamine reuptake inhibitors}}{{Muscarinic acetylcholine receptor modulators}}2. ^{{cite journal|last1=DiMascio|first1=A.|last2=Bernardo|first2=D. L.|last3=Greenblatt|first3=D. J.|last4=Marder|first4=J. E.|title=A controlled trial of amantadine in drug-induced extrapyramidal disorders|journal=Archives of General Psychiatry|date=1976|volume=33|issue=5|pages=599–602|issn=0003-990X|doi=10.1001/archpsyc.1976.01770050055008|pmid=5066}} 3. ^{{cite journal|last1=Wilson|first1=DV|last2=Nickels|first2=FA|last3=Williams|first3=MA|title=Pharmacologic treatment of priapism in two horses|journal=Journal of the American Veterinary Medical Association|date=1 Nov 1991|pages=1183–4|accessdate=}} 4. ^{{ Cite journal |vauthors=Kane JM, Smith JM | title = Tardive dyskinesia: Prevalence and risk factors, 1959 to 1979 | journal = Archives of General Psychiatry | year = 1982 | volume = 39 | issue = 4 | pages = 473–81 | pmid = 6121548 | doi=10.1001/archpsyc.1982.04290040069010}} 5. ^{{cite journal |vauthors=Wszola BA, Newell KM, Sprague RL | title = Risk factors for tardive dyskinesia in a large population of youths and adults | journal = Experimental and Clinical Psychopharmacology | year = 2001 | volume = 9 | issue = 3 | pages = 285–96 | pmid = 11534539 | doi = 10.1037/1064-1297.9.3.285 }} 6. ^{{cite journal |vauthors=van Harten PN, Hoek HW, Matroos GE, Koeter M, Kahn RS | title = Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curaçao Extrapyramidal Syndromes Study III | journal = The American Journal of Psychiatry | year = 1998 | volume = 155 | issue = 4 | pages = 565–7 | pmid = 9546009 | doi = 10.1176/ajp.155.4.565 }} 7. ^{{cite journal | author = Yassa R | title = Tardive dyskinesia and anticholinergic drugs. A critical review of the literature | journal = L'Encéphale | year = 1988 | volume = 14 | issue = Spec No | pages = 233–9 | pmid = 3063514 }} 8. ^{{cite journal |vauthors=Gelenberg AJ, Van Putten T, Lavori PW, Wojcik JD, Falk WE, Marder S, Galvin-Nadeau M, Spring B, Mohs RC, Brotman AW | title = Anticholinergic effects on memory: benztropine versus amantadine. | journal = Clinical Psychopharmacology | year = 1989 | volume = 9 | issue = 3 | pages = 180–5 | pmid = 2661606 | doi = 10.1097/00004714-198906000-00004 }} 9. ^MIMS Australia Pty Ltd. MIMS. 10. ^{{cite journal |vauthors=Hiranita T, Kohut SJ, Soto PL, Tanda G, Kopajtic TA, Katz JL | title = Preclinical efficacy of N-substituted benztropine analogs as antagonists of methamphetamine self-administration in rats| journal = J Pharmacol Exp Ther| year = 2014 | volume = 348 | issue = 1 | pages = 174–91 | doi = 10.1124/jpet.113.208264 | pmid = 24194527 | pmc = 3868882 }} 11. ^{{cite journal | title = A controlled comparison of the effects of propranolol, benztropine, and placebo on akathisia: an interim analysis.| year = 1993 | pmid = 8290678 | volume=29 | journal=Psychopharmacol Bull | pages=283–6 | vauthors=Adler LA, Peselow E, Rosenthal M, Angrist B}} 12. ^{{cite journal |vauthors=Kornhuber J, Muehlbacher M, Trapp S, Pechmann S, Friedl A, Reichel M, Mühle C, Terfloth L, Groemer T, Spitzer G, Liedl K, Gulbins E, Tripal P | title = Identification of novel functional inhibitors of acid sphingomyelinase | journal = PLoS ONE | year = 2011 | volume = 6 | issue = 8 | pages = e23852 | doi = 10.1371/journal.pone.0023852 | pmid = 21909365 | pmc = 3166082 }} 13. ^{{cite journal |vauthors=Deshmukh VA, Tardif V, Lyssiotis CA, Green CC, Kerman B, Kim HJ, Padmanabhan K, Swoboda JG, Ahmad I, Kondo T, Gage FH, Theofilopoulos AN, Lawson BR, Schultz PG, Lairson LL | title = A regenerative approach to the treatment of multiple sclerosis | journal = Nature | year = 2013 | volume = 502 | issue = 7471 | pages = 327–332 | doi = 10.1038/nature12647 | pmid = 24107995 | pmc=4431622}} 6 : Dopamine reuptake inhibitors|Ethers|Muscarinic antagonists|Tardive dyskinesia|Tropanes|Oneirogens |
| 随便看 |
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。